tert-butyl [4-(2-hydroxyethyl)-6-methoxypyridin-3-yl]carbamate | 727993-72-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: tert-butyl [4-(2-hydroxyethyl)-6-methoxypyridin-3-yl]carbamate
• 英文别名: tert-butyl N (4-(2-hydroxy-ethyl)-6-methoxy-pyridin-3-yl)carbamate；2-[5-(Boc-amino)-2-methoxy-4-pyridyl]ethanol；tert-butyl N-[4-(2-hydroxyethyl)-6-methoxypyridin-3-yl]carbamate
• CAS: 727993-72-8
• 化学式: C₁₃H₂₀N₂O₄
• 分子量: 268.313
• InChiKey: SWWDWKVINFZOTG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  80.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl [4-(2-hydroxyethyl)-6-methoxypyridin-3-yl]carbamate 在 三乙胺 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 2.33h， 生成 tert-butyl 5-methoxy-2,3-dihydro-1H-pyrrolo[2,3-c]pyridine-1-carboxylate
  参考文献：
  名称：

  二酰甘油激酶抑制剂及其用途

  摘要：

  本发明属于医药技术领域，具体涉及一类可用作二酰甘油激酶抑制剂的化合物、其药学上可接受的盐、其酯或其立体异构体，含有所述化合物、其药学上可接受的盐、其酯或其立体异构体的药物组合物及制剂，制备所述化合物、其药学上可接受的盐、其酯或其立体异构体的方法，以及所述化合物、其药学上可接受的盐、其酯或其立体异构体在制备治疗和/或预防由二酰基甘油激酶介导的疾病及相关疾病的药物中的用途。#imgabs0#

  公开号：

  CN117088874A
• 作为产物：
  描述：

  5-氨基-2-甲氧基吡啶 在 正丁基锂 、 四甲基乙二胺 作用下， 以 1,4-二氧六环 、 乙醚 为溶剂， 生成 tert-butyl [4-(2-hydroxyethyl)-6-methoxypyridin-3-yl]carbamate
  参考文献：
  名称：

  New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors

  摘要：

  DOI：

  10.1016/j.bmcl.2004.03.067

文献信息

• Azabenzodiazepines as pde4 inhibitors
  申请人：Warner-Lambert Company LLC

  公开号：EP1526135A1

  公开（公告）日：2005-04-27

  Compounds of formula (I): characterized in that: R1 represents a group selected from hydrogen atom, methyl, methoxy, hydroxy, amino, dimethylamino, acetamido, pyrrolidin-1-yl, and hydroxymethyl; R2 represent a group selected from phenyl, pyridyl, pyrimidyl, quinolyl, isoquinolyl, indolyl, pyrolyl, [1,2,3]-triazolyl, benzo[c]isoxazolyl, thienyl, pyrazolyl, isothiazolyl, imidazolyl, benzofuranyl, pyrazolo[5,1-c][1,2,4]triazyl each of these groups being optionally substituted from 1 to 3 groups, identical or different independently of each other, selected from halogen, trifluoromethyl, (C1-C4)alkyl, (C1-C4)alkoxy, hydroxy, amino, acetamido, tert-butyloxycarbonylamino, cycloalkylcarbonylamino, sulfonamide, nitro, acetylmethoxy, cyclopentyloxy; optionally, their optical isomers, and addition salts thereof with a pharmaceutically acceptable acid or base, and their use as active ingredient in pharmaceutical composition useful for treating diseases involving therapy by inhibition of PDE4.

  式（I）化合物的特征在于：R1代表从氢原子、甲基、甲氧基、羟基、氨基、二甲胺基、乙酰胺基、吡咯烷-1-基和羟甲基中选择的基团；R2代表从苯基、吡啶基、嘧啶基、喹啉基、异喹啉基、吲哚基、吡咯基、[1,2,3]-三唑基、苯并[c]异噁唑基、噻吩基、吡唑基、异噻唑基、咪唑基、苯并呋喃基、吡唑并[5,1-c][1,2,4]三唑基中选择的基团，这些基团中的每一个可以从1到3个独立选择的卤素、三氟甲基、（C1-C4）烷基、（C1-C4）氧基、羟基、氨基、乙酰胺基、叔丁氧羰胺基、环烷基羰胺基、磺酰胺基、硝基、乙酰甲氧基、环戊氧基进行选择的取代基；可选地，它们的光学异构体，以及它们与药学上可接受的酸或碱形成的加合物，以及它们作为药用组合物中的活性成分的用途，用于治疗涉及通过抑制PDE4进行治疗的疾病。
• Preparation of azaindolines and benzoyl substituted azaindolines: precursors of triazabenzo[cd]azulen-9-one PDE4 inhibitors
  作者：Matthew Badland、Ingrid Devillers、Corinne Durand、Véronique Fasquelle、Bernard Gaudillière、Henry Jacobelli、Ajith C. Manage、Isabelle Pevet、Jocelyne Puaud、Anthony J. Shorter、Roger Wrigglesworth

  DOI：10.1016/j.tetlet.2011.08.009

  日期：2011.10

  The syntheses of various substituted azaindolines are described. Azaindolines were identified as potential key intermediates towards new PDE4 inhibitors. (C) 2011 Elsevier Ltd. All rights reserved.
• [EN] AZABENZODIAZEPINES AS PHOSPHODIESTERASE-4 INHIBITORS<br/>[FR] AZABENZODIAZEPINES A TITRE D'INHIBITEURS DE LA PHOSPHODIESTERASE-4
  申请人：WARNER LAMBERT CO

  公开号：WO2005040168A1

  公开（公告）日：2005-05-06

  Compounds of formula (I): characterized in that: • Rl represents a group selected from hydrogen atom, methyl, methoxy, hydroxy, amino, dimethylamino, acetamido, pyrrolidin-l-yl, and hydroxymethyl; • R2 represent a group selected from phenyl, pyridyl, pyrimidyl, quinolyl, isoquinolyl, indolyl, pyrolyl, [1,2,3]-triazolyl, benzo[c]isoxazolyl, thienyl, pyrazolyl, isothiazolyl, imidazolyl, benzofuranyl, pyrazolo[5,1-c][1,2,4]triazyl each of these groups being optionally substituted from 1 to 3 groups, identical or different independently of each other, selected from halogen, trifluoromethyl, (C1-C4)alkyl, (CI-C4)alkoxy, hydroxy, amino, acetamido, tert-butyloxycarbonylamino, cycloalkylcarbonylamino, sulfonamide, nitro, acetylmethoxy, cyclopentyloxy; optionally, their optical isomers, and addition salts thereof with a pharmaceutically acceptable acid or base, and their use as active ingredient in pharmaceutical composition useful for treating diseases involving therapy by inhibition of PDE4.
• [EN] TRANS-DECAHYDROISOQUINOLINE DERIVATIVES<br/>[FR] DÉRIVÉS DE TRANS-DÉCAHYDROISOQUINOLINE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2009034546A2

  公开（公告）日：2009-03-19

  The invention relates to antibacterial compounds of formula (I) wherein R1 is alkoxy, one or two of U, V, W, X represent(s) N, the remaining represents CH, whereby V may also represent CRa, W may also represent CRb and X may also represent CRC, Ra is hydroxyalkyl; Rb is alkoxycarbonyl, carboxy or hydroxyalkyl; Rc is halogen, R2 is alkoxycarbonyl, carboxy, hydroxyalkyl or aminoalkyl, A is CH2B, C(=O)B or CH2CH=CHD, B is the group (II) wherein Z is N or CH and the ring P is selected from the formula (III) in which Q is O or S, and D is aryl (e.g. 1,4-difluoro-2 -phenyl).